Acromegaly
Conditions
Keywords
pegvisomant, pasireotide LAR, long acting somatostatin analogues
Brief summary
The objective of this study is to assess the efficacy of Pasireotide Long Acting Release (LAR) alone and in combination with weekly Pegvisomant (PEGV) in acromegaIy patients previously controlled with combination treatment of long-acting Somatostatin analogs (LA-SSAs) and PEGV.
Detailed description
Pasireotide Long Acting Release (Signifor ®), a novel long-acting multi-receptor ligand somatostatin analogue, has been shown to be more effective for the treatment of GH-secreting pituitary adenomas than currently used long-acting somatostatin analogues (LA-SSAs). The long-term efficacy of acromegaly patients using LA-SSAs in combination with PEGV was over 90% in terms of normalization of IGF-I. The combination of PEGV with pasireotide LAR has not been studied yet. Combining PEGV with pasireotide LAR could result in a lower dose and less injections of pegvisomant. This may ultimately lead to a more cost-effective treatment and improved quality of life.
Interventions
as mono-therapy or in combination with pegvisomant
DRUGPegvisomant
only in combination with pasireotide LAR
Sponsors
Novartis
Erasmus Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* written informed consent male or female aged ≥ 18 years * documentation supporting the diagnosis of acromegaly based on elevated GH and/or IGF-I levels due to a pituitary tumor * the patient is treated with lanreotide Autogel or octreotide LAR and PEGV (twice) weekly for at least 6 months and has a serum IGF-I level within 120 % of the age adjusted normal limits. These patients were previously not controlled by somatostatin analogs alone. * female of no childbearing potential or male. No childbearing potential is defined as being postmenopausal for at least 1 year, or women with documented infertility (natural or acquired) or using two acceptable contraceptive measures, except for oral contraceptives. * male subjects must agree that, if their partner is at risk of becoming pregnant, they will use a medically accepted, effective method of contraception (i.e. use a condom) for the duration of the study * subjects must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period and willing to return to the clinic for the follow up evaluation as specified in the protocol.
Exclusion criteria
Patients will not be included in the study if he or she: * has undergone pituitary surgery or radiotherapy within 6 months prior to study entry. * it is anticipated that the patient will receive pituitary surgery or radiotherapy during the study. * has a history of hypersensitivity to lanreotide, octreotide or pegvisomant or drugs with a similar chemical structure * has been treated with any unlicensed drug within the last 30 days before study entry. * has abnormal hepatic function at study entry (defined as AST, ALT, gGT, alkaline phosphatase, or total bilirubin above 3 ULN) * is at risk of pregnancy or is lactating. Females of childbearing potential must provide a negative pregnancy test within 5 days before the start of the study and must be using contraception. Non-childbearing potential is defined as post-menopause for at least one year, surgical sterilization or hysterectomy at least three months before the start of the study. * has a history of, or known current problems with alcohol or drug abuse. * has a mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude. * has abnormal baseline findings, any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might jeopardize the subject's safety or decrease the chance of obtaining satisfactory data needed to achieve the objective(s) of the study. * renal insufficiency, clearance \< 50ml/min * poorly controlled diabetes mellitus with an HbA1c \> 9.0% * patients with a QTc \> 500 ms on the EKG * participation in a clinical trial in the last 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients with normalized IGF1 levels at 24 weeks in the pasireotide LAR monotherapy group and in the pasireotide LAR combined with pegvisomant group | 24 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The proportion of patients with normalized IGF1 levels after 48 weeks combination treatment of pasireotide LAR with weekly pegvisomant. | 48 weeks | — |
| The necessary dose of pegvisomant during combination treatment of pasireotide LAR with pegvisomant in patients with an IGF-I level within the age adjusted normal limits | 48 weeks | — |
| Change in tumor volume by pituitary MRI | Baseline and 48 weeks | — |
| The proportion of patients with normalized IGF1 levels after 48 weeks of pasireotide LAR monotherapy | 48 weeks | — |
| Tolerability and safety profile of pasireotide LAR and pegvisomant combination therapy | 48 weeks | Toxicity will be assessed using the National Cancer Institute-Common Toxicology Criteria Adverse Events version 4 (NCI-CTCAE v.4.03) and for laboratory assessments that include biochemistry, hematology, urinalysis; special safety assessments that include the regular monitoring and recording of blood glucose, insulin, HbA1c, and IGF-1, thyroid and liver function tests, gallbladder examinations and ECGs. Concomitant medications/Significant nondrug therapies will be assessed from study enrollment until the safety follow-up. |
| Evaluation of long term effect of pasireotide LAR with or without pegvisomant on AcroQol, PASQ and signs and symptoms of acromegaly | Change in scores as measured by AcroQoL from baseline to week 48 | AcroQol is quality of life questionnaire specifically designed for acromegaly |
| Evaluation of body composition by Dual-energy X-ray Absorptiometry (DEXA) scan | baseline and 48 weeks | — |
| Tolerability and safety profile of pasireotide Long Acting Release (LAR) monotherapy | 48 weeks | Toxicity will be assessed using the National Cancer Institute-Common Toxicology Criteria Adverse Events version 4 (NCI-CTCAE v.4.03) and for laboratory assessments that include biochemistry, hematology, urinalysis; special safety assessments that include the regular monitoring and recording of blood glucose, insulin, HbA1c, GH and IGF-1, thyroid and liver function tests, gallbladder examinations and ECGs. Concomitant medications/Significant nondrug therapies will be assessed from study enrollment until the safety follow-up. |
Countries
Netherlands
Outcome results
None listed